Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial targets deadly inflammation in HIV patients

NCT ID NCT06052618

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times

Summary

This study tests a drug called pacritinib for people with HIV who have two rare, serious conditions caused by a virus (KSHV): multicentric Castleman disease (MCD) and inflammatory cytokine syndrome (KICS). These conditions cause severe inflammation that can be life-threatening. The drug is taken as a capsule twice daily for up to 24 weeks. The goal is to see if pacritinib can reduce symptoms and control the disease. 75 adults with at least one symptom are being recruited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KSHV INFLAMMATORY CYTOKINE SYNDROME (KICS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

KAPOSI SARCOMA HERPESVIRUS -ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE KAPOSI SARCOMA HERPESVIRUS -ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE KSHV INFLAMMATORY CYTOKINE SYNDROME (KICS)